| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51f95273815aea14e23dffd10ffc2208 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2016-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd97314f5a0c654f2cb78ee8b54c67e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34ef783cf81f263af8d727b1e4e24b9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38964c7c27750d25de5da2c6cf51ab67 |
| publicationDate |
2016-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016203061-A1 |
| titleOfInvention |
Reduction in deallylation of naloxone during storage of a sustained-release formulation containing naloxone |
| abstract |
The present invention relates to: a packaged drug comprising a pharmaceutical sustained-release formulation of naloxone or of a pharmaceutically acceptable salt thereof and a packaging; a method for producing a drug with high storage stability, the method comprising the packaging of a sustained-release formulation of naloxone or of a pharmaceutically acceptable salt thereof; the use of a packaging for stabilising the storage of a drug comprising a pharmaceutical sustained-release formulation of naloxone or of a pharmaceutically acceptable salt thereof; and also the use of a packaging for reducing the deallylation of naloxone or of the pharmaceutically acceptable salt thereof during the storage of a pharmaceutical sustained-release formulation of naloxone or of a pharmaceutically acceptable salt thereof. |
| priorityDate |
2015-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |